Jade Biosciences (NASDAQ:JBIO) Shares Down 9.6% - What's Next?

Key Points

• Jade Biosciences shares fell 9.6% to about $15.15, with trading volume down 84% from its average. The stock remains below its 50-day and 200-day moving averages.
• Analyst sentiment is mixed: some firms maintain “buy” ratings with price targets of $45–$48, while Weiss Ratings rates it “sell” and Wall Street Zen downgraded it to “strong sell.” The consensus rating is “Moderate Buy” with a $51.75 price target.
• The clinical-stage biotechnology company reported a quarterly loss of $0.76 per share, missing estimates by $0.10, and analysts expect a full-year loss of $2.84 per share. Jade has no commercially marketed products and is focused on autoimmune and inflammatory disease therapies.

Jade Biosciences, Inc. (NASDAQ:JBIO - Get Free Report)'s share price was down 9.6% on Wednesday . The stock traded as low as $15.22 and last traded at $15.15. Approximately 119,322 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 742,858 shares. The stock had previously closed at $16.76.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on JBIO shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Jade Biosciences in a research report on Friday, September 11th. Wall Street Zen cut shares of Jade Biosciences from a "sell" rating to a "strong sell" rating in a research report on Saturday, September 12th. Jefferies Financial Group reiterated a "buy" rating and issued a $48.00 price target on shares of Jade Biosciences in a research report on Tuesday, August 11th. Guggenheim restated a "buy" rating and set a $47.00 price objective on shares of Jade Biosciences in a research report on Tuesday, June 2nd. Finally, UBS Group initiated coverage on Jade Biosciences in a research note on Monday, June 15th. They issued a "buy" rating and a $45.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $51.75.

Jade Biosciences Price Performance

The stock has a market cap of $941.66 million, a price-to-earnings ratio of -7.69 and a beta of 1.45. The stock's 50-day moving average is $20.43 and its 200-day moving average is $19.73.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.10). Analysts predict that Jade Biosciences, Inc. will post -2.84 EPS for the current fiscal year.

Institutional Trading of Jade Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Engineers Gate Manager LP acquired a new stake in shares of Jade Biosciences in the second quarter worth approximately $503,000. Maven Securities LTD purchased a new position in shares of Jade Biosciences in the 2nd quarter worth $1,111,000. Squarepoint Ops LLC boosted its holdings in Jade Biosciences by 22.0% in the second quarter. Squarepoint Ops LLC now owns 54,456 shares of the company's stock valued at $1,210,000 after acquiring an additional 9,806 shares during the last quarter. Corient Private Wealth LP acquired a new position in Jade Biosciences in the second quarter valued at $1,367,000. Finally, Bank of New York Mellon Corp purchased a new stake in Jade Biosciences during the second quarter valued at about $1,896,000.

About Jade Biosciences

Jade Biosciences, Inc NASDAQ: JBIO is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. The company uses antibody-based drug discovery and development approaches to pursue therapies intended to address significant unmet medical needs.

Jade Biosciences is advancing a pipeline of investigational programs and does not currently have commercially marketed products. Its work is centered on identifying and developing targeted therapies that may modulate biological pathways involved in autoimmune disease.

The company's activities primarily consist of research, preclinical development and clinical evaluation of its drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.